title: [The study of the effectiveness of drug prevention mechanisms of cardiovascular aging by cytoflavin].
abstract: The aim of the research was the search of the mechanism of Cytoflavin action in patients with isolated systolic arterial hypertension (ISAH) as the aging model. The following research methods were applied: the assessment of complaints, 24-hour arterial pressure monitoring, ultrasound diagnostic, volume sphygmography, lipid profiles and coagulogram, molecular phenotyping by MALDI-TOF-TOF-MS. The combination of Cytoflavin with standard therapy of ISAH led to the most expressed return development of clinical symptoms, the restoration of the haemodynamics, structural and geometrical parameters of cardiovascular system, indicators lipid profiles and coagulogram in the comparison with patients with ISAH, who accepted standard therapy and those of the control groups. Molecular mechanisms of Cytoflavin action, including regulation of the activity of cell signaling pathways through intermolecular interactions were found. We recommend using Cytoflavin together with the standard therapy in treatment of ISAH, which provides the action of geroprotectors for cardiovascular system.
authors.forename: E A
authors.initials: EA
authors.lastname: Kartashova
authors.forename: M G
authors.initials: MG
authors.lastname: Romantsov
authors.forename: I V
authors.initials: IV
authors.lastname: Sarvilina
mesh_terms: D000368:Aged; D000375:Aging / Q000097:blood / Q000187:drug effects* / Q000473:pathology; D001777:Blood Coagulation / Q000187:drug effects; D001783:Blood Flow Velocity / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D018660:Blood Pressure Monitoring, Ambulatory; D001921:Brain / Q000098:blood supply; D002319:Cardiovascular System / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D002560:Cerebrovascular Circulation / Q000187:drug effects; D015331:Cohort Studies; D004338:Drug Combinations; D005260:Female; D005486:Flavin Mononucleotide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000473:pathology / Q000517:prevention & control*; D007290:Inosine Diphosphate / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D009536:Niacinamide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011446:Prospective Studies; D020543:Proteome / Q000378:metabolism; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D013386:Succinates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D017585:Ultrasonography, Doppler, Transcranial
chemical_list: D004338:Drug Combinations; D008055:Lipids; D020543:Proteome; D013386:Succinates; C507879:cytoflavin; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate